XWELL, Inc.

XWEL Healthcare Diagnostics & Research

XWELL, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.2 million, down 13.8% from fiscal 2024.

Revenue
−7.08%
EPS
+53.6%
Free cash flow
−43.0%

Quarter to June 2026, against a year earlier

0.56 0.01 −1.75%
Market cap
$6.1M
P/E
0.0×
Fwd P/E
−4.4×
Dividend yield
—
F-score
3/9
Altman Z
−63.81
Beneish M
−6.38
Dividend safety
0/100
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
5 5 3 3

+8 more TTM periods

ROE
(557.21%) (527.56%) 1,115.49% (194.43%)
ROA
(155.10%) (137.00%) (154.41%) (62.65%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(330.69%) (259.88%) 530.99% (374.73%)
Average Days of Receivables
23.54 16.68 19.49 18.33
Free Cash Flow per Share
(1.59) (1.63) (2.10) (2.62)
Free Cash Flow
(13.48) (12.07) (11.68) (15.12)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 25 Oct 2026